Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 6/20 | 0.61 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16789085 | 0.93 | CHRM3 (0.62) | CHRM3CHRNA7BCHEACHECHRM2 | |
| SCHEMBL8510174 | 0.88 | CHRM3 (0.63) | CHRM3CHRNA7BCHEACHECHRM2 | |
| SCHEMBL8510178 | 0.88 | CHRM3 (0.63) | CHRM3CHRNA7BCHEACHECHRM2 | |
| SCHEMBL8512405 | 0.87 | CHRM3 (0.65) | CHRM3CHRNA7BCHEACHECHRM2 | |
| SCHEMBL8512408 | 0.87 | CHRM3 (0.65) | CHRM3CHRNA7BCHEACHECHRM2 | |
| SCHEMBL8509919 | 0.85 | CHRM3 (0.60) | CHRM3CHRNA7BCHEACHECHRM2 | |
| SCHEMBL8509921 | 0.85 | CHRM3 (0.60) | CHRM3CHRNA7BCHEACHECHRM2 | |
| SCHEMBL8509486 | 0.85 | CHRM3 (0.57) | CHRM3CHRNA7BCHEACHECHRM2 | |
| SCHEMBL8509484 | 0.85 | CHRM3 (0.57) | CHRM3CHRNA7BCHEACHECHRM2 | |
| SCHEMBL8509480 | 0.85 | CHRM3 (0.62) | CHRM3CHRNA7BCHEACHECHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772314-B2 | Glycine derivatives and medicinal compositions thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-07-08 | — | — | US | disclosed |
| US-20120134934-A1 | GLYCINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134934-A1 | GLYCINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | CHRM3, GLRB, CHRNG | CHRM3 1/4885CHRNA7 48/4885BCHE 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.